Rick Wilson, Director of the Genome Sequencing Center, Washington University
The process by which we discover, optimize, develop, manufacture and market new medicines is fundamentally changing. Some believe this will lead to more efficient, targeted treatment regimens ultimately creating a more vibrant, responsive and robust healthcare economy. Others say these changes will cause a fundamental shift in the economics of drug development and could severely dampen investor enthusiasm in the industry.
If the real future lies somewhere in between, what can the major stakeholders in translational medicine do to encourage adoption of systems and processes that will accelerate the rate of innovation towards a more efficient therapeutic development model?
10:00 – 10:30am Networking Break Khorassan West
10:30am – 12:00pm Plenary Session Khorassan East
The Changing Landscape: New Models for Funding Translational Research Moderator: Lesa Mitchell, Vice President, Advancing Innovation, Kauffman Foundation
Panelists: Robert Beall, President & CEO, Cystic Fibrosis Foundation
Deborah Brooks, Co-Founder, Michael J. Fox Foundation
Laura Heisler, Intellectual Property Manager, Wisconsin Alumni Research Foundation (WARF)
Jamie Heywood, Founding Director of d'Arbeloff & Former CEO, ALS Therapy Development Institute
Dennis Purcell, Senior Managing Director, Aisling Capital
Robert Zivin, Corporate Director, Corporate Office of Science & Technology, Johnson & Johnson
Disease foundations and other non-industry, non-government sources now play a critical role in funding and supporting early-stage research. Explore some of the newer investment models that support breakthrough translational medicine and the issues involved in meshing diverse sources of funds with differing agendas.
As major research universities diversify their funding base beyond dependence on RO1s, how can they find other sources of funding for their most promising research? What are these sources of funding -- foundations, corporate sponsors, public and private investment funds? How do we reconcile near-term return objectives with philanthropic objectives?
12:00 – 1:30pm Lunch Khorassan East
Roundtable of National Leaders: Future of Medicine: Can the modern healthcare economy adapt to accelerating technological change?
Moderator: William Peck, Director, Center for the Study of Health Policy, Washington University
Panelists: Peter Corr, Corporate Senior Vice President for Science & Technology, Pfizer Inc. (retired)
Harlan Krumholz, Harold H. Hines, Jr. Professor of Medicine, Epidemiology & Public Health, and Director, Robert Woods Johnson Clinical Scholars Program, Yale University
Garry Neil, Group President of the CNS-IM Franchise, Johnson & Johnson Pharmaceuticals Development Corp.
Ralph Snyderman, Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine, Duke University School of Medicine
Roundtable 1: Institutional Policy & Practice Supporting Translational Research Empire Room
Moderator: Lesa Mitchell, Vice President, Advancing Innovation, Kauffman Foundation
Panelists: Katharine Ku, Director of the Office of Technology Licensing, Stanford University
Jose Olivares, Deputy Division Leader, Bioscience Division, Los Alamos National Laboratory
John Parrish, Director & Founder, Center for Integration of Medicine & Innovative Technology (CIMIT)
Tom Stossel, American Cancer Society Professor of Medicine, Harvard Medical School & Director, Translational Medicine Division, Brigham & Women's Hospital
Robert Taber, Vice Chancellor of Corporate & Venture Development, Duke University
What is the best measure of the success of a research institution's commercialization strategy: number of disclosures, patents, licenses or companies created? Examine the strategies of many of the leading institutions that are funding translational research and commercializing technology. Where does translational medicine work best? What are the greatest challenges? What is the best framework for managing the IP, handling material transfer agreements, and determining the direction of the research? What are the best ways to encourage and work with entrepreneurial faculty, create and fund start-up companies from university technology, and effectively use internal and external translational research funds?
Moderator: Mark Goldberg, Director of the Hope Center for Neurological Disorders, Washington University
Panelists: Marc Cochran, CEO & Executive Director, Blanchette Rockefeller Neurosciences Institute
Gene Johnson, Professor of Neurology, and of Molecular Biology & Pharmacology, Washington University
Karl Kieburtz, Professor of Neurology and of Community & Preventive Medicine, University of Rochester Medical Center
Eric Siemers, Medical Director, Alzheimer's Disease Team, Eli Lilly and Company
James Wang, Vice President of Discovery Sciences, High Q Foundation
Roundtable 3: Cardiovascular Plaza Room
Moderator: Dennis Wahr, RiverVest Venture Partners
Panelists: Alan Bentley, Director of Commercialization, Cleveland Clinic
Joel Braunstein, CEO, LifeTech Research
Harlan Krumholz, Professor of Medicine, Epidemiology & Public Health, Yale University
Achi Ludomirsky, Pediatrics & Biomedical Engineering, St. Louis Children's Hospital
Jerry Millhon, Executive Director, Pacific Vascular Research Foundation
Disease and technology focused sessions will explore translational research models in practice in thirteen different research disciplines. Each session will be led by a top researcher who will initiate discussion around a number of topics related to the major issues involved in supporting successful translational research.
Several investigators will be invited to briefly summarize their research and talk about their strategies for moving their work towards clinical development and commercialization.
Roundtable 4: Collaborative Models in Translational Research Empire Room
Moderator: Frank Douglas, Founder & First Executive Director, MIT Center for Biomedical Innovation
Panelists: Anthony Atala, W.H. Boyce Professor & Director of the Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine
Donald Lombardi, CEO, Pediatric Innovation Institute
Art Mellor, President, Accelerated Cure Project for Multiple Sclerosis
Scott Santarella, COO, Multiple Myeloma Research Foundation & Multiple Myeloma Research Consortium
Sam Wickline, Director, Siteman Center for Cancer Nanotechnology Excellence, Washington University
More effective models to support translational medicine will largely depend on collaborative research structures that leverage research activities across multiple institutions. How do we promote more multi-institutional and university-company collaborations?
Examine some of the existing collaborative research models and their inherent benefits and challenges: How should we fund pre-competitive collaborative research? Are industry and/or foundation supported research consortia the most effective way to produce pre-competitive discoveries (e.g., biomarkers, validated targets, toxicity studies, molecular libraries, etc.)? How should we manage tissue banks and associated medical histories; identification and standardization of biomarkers; and other collaborative research tools?
Roundtable 5: Rare Diseases Lenox Room
Moderator: Brian Clevinger, Founder & Managing Director, Prolog Ventures
Panelists: Robert Beall, President & CEO, Cystic Fibrosis Foundation
Rashmi Gopal-Srivastava, Director of Extramural Research Program, Office of Rare Diseases, National Institutes of Health
Jamie Heywood, Founding Director of d'Arbeloff & Former CEO, ALS Therapy Development Institute
Jon LeBowitz, CSO, ZyStor Therapeutics
Stuart Peltz, President & CEO, PTC Therapeutics
Roundtable 6: Devices Plaza Room
Moderator: Philippe Sommer, Director of Entrepreneurship Programs, Batten Institute, University of Virginia
Panelists: Janice Crosby, Director, Business Development, CIMIT
John Linehan, Consulting Professor of Bioengineering, Program in Biodesign, Stanford University
Banu Onaral, H. H. Sun Professor of Biomedical Engineering & Electrical Engineering, Drexel University
Tom Skalak, Professor & Chair of the Department of Biomedical Engineering, University of Virginia
6:30 – 10:00pm Reception & Dinner
6:30pm Bus Loading at Lindell Avenue Entrance
7:00 - 10:00pm Lakeside Café, St. Louis Zoo
Attendees will sign-up to sit at a table hosted by a noted individual in science, industry, government, philanthropy or investment.
TUESDAY, SEPTEMBER 11
7:00am Continental Breakfast Khorassan West
8:00 – 9:15am Plenary Session Khorassan East
Partnering Effectively with Industry Moderator: David Rosen, Developmental & Commercial Head of Strategic Alliances, Pfizer Inc.
Panelists: Joni Catalano-Sherman, Corporate Director, Science & Technology, Johnson & Johnson J-C Health Care Ltd.
Joyce Cramer, President, Epilepsy Therapy Development Project
Stuart Peltz, President & CEO, PTC Therapeutics
Ward Peterson, Vice President of Research & Preclinical Development, Inspire Pharmaceuticals
Tom Skalak, Professor & Chair of the Department of Biomedical Engineering, University of Virginia
Most experts acknowledge that if we are to improve the productivity of drug discovery and development systems globally, we need to develop more effective ways of directing industry experience and resources towards the earliest stages – the university.
What are the most successful models for industry-sponsored research? How do we assess the value of untargeted verses targeted corporate funding of university research? Can industry play a more active role in translational research without stifling the innovative culture? Can development-stage programs be managed in a university setting through proof of concept? What are best practices for win-win structures for university-industry collaborations?
Moderator: Katherine Gordon, Director of Business Development, Office of Technology Development, Harvard Medical School
Panelists: Denise Faustman, Director, Immunology Labs, Massachusetts General Hospital
Samuel Klein, Chief of the Division of Geriatrics & Nutritional Sciences, Washington University School of Medicine
William Lowe, Interim Chair, Department of Medicine, Northwestern University
Leslie Molony, Co-Founder, President & CEO, Transgeneron Therapeutics, Inc.
Roundtable 14: Infectious Disease Plaza Room
Moderator: Sam Stanley, Vice Chancellor for Research, Washington University
Panelists: Robert Belshe, Director & Professor, Division of Infectious Diseases and Immunology, Saint Louis University
Praveen Tipirneni, Head of Corporate & Business Development, Cubist Pharmaceuticals
Geoff Waldo, Technical Staff in Biosciences, Los Alamos National Laboratory
Roundtable 15: Cancer: Hematologic Empire Room
Moderator: Edward Allera, Managing Shareholder, Buchanan, Ingersoll & Rooney
Panelists: Camille Abboud, Professor of Medicine, Division of Oncology, Siteman Cancer Center, Washington University School of Medicine
Anthony Letai, Clinician & Researcher of Hematologic Oncology, Medical Oncology & Hematologic Neoplasia, Dana-Farber Cancer Institute, Harvard Medical School
David Livingston, Senior Vice President of Biology & Head of Biodetection, Ensemble Discovery Corporation
Linda JZ Penn, Head Division of Cancer Genomics & Proteomics, Ontario Cancer Institute
